← Eichor
Study identifier: NCT04481256 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY

Condition: Carcinoma, Squamous Cell · Oesophageal Cancer  ·  Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

PhaseNA
Planned participants49
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The primary objective of this study is to assess the feasibility of treatment with bintrafusp alfa combined with definitive chemoradiation (carboplatin, paclitaxel and radiation) in patients with squamous cell carcinoma of the esophagus or gastroesophageal junction.

This description comes directly from the study's public registry record.

Talk to the study team

Linde M Veen, MD  ·  +31 20 4443312  ·  l.veen1@amsterdamumc.nl

Hanneke WM van Laarhoven, MD, PhD  ·  +31 20 5665955  ·  h.vanlaarhoven@amsterdamumc.nl

Always discuss trial participation with your own doctor first.

Locations (1)

Academic Medical Center, Medical OncologyAmsterdam, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04481256